Translating vaccine policy into action: A report from the Bill & Melinda Gates Foundation Consultation on the prevention of maternal and early infant influenza in resource-limited settings |
| |
| Authors: | Justin R. Ortiz |
| |
| Affiliation: | 1. PATH, PO Box 900922, Seattle, WA 98109, USA;2. University of Washington, Box 356420, 1959 NE Pacific St., Seattle, WA 98195-6522, USA;3. PATH, PO Box 900922, Seattle, WA 98109, USA;4. University of Washington, Box 356420, 1959 NE Pacific St., Seattle, WA 98195-6522, USA; Bill & Melinda Gates Foundation, PO Box 23350, Seattle, WA 98102, USA; National Vaccine Program Office, Office of the Assistant Secretary for Health, Office of the Secretary, U.S. Department of Health and Human Services; 200 Independence Ave. SW, Washington, DC 20201, USA; Department of Health, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK; National Vaccine Program Office, Office of the Assistant Secretary for Health, Office of the Secretary, U.S. Department of Health and Human Services; 200 Independence Ave. SW, Washington, DC 20201, USA; Bill & Melinda Gates Foundation, PO Box 23350, Seattle, WA 98102, USA; Wake Forest Baptist Medical Center. Medical Center Boulevard. Winston-Salem, NC 27157, USA |
| |
| Abstract: | Immunization of pregnant women against influenza is a promising strategy to protect the mother, fetus, and young infant from influenza-related diseases. The burden of influenza during pregnancy, the vaccine immunogenicity during this period, and the robust influenza vaccine safety database underpin recommendations that all pregnant women receive the vaccine to decrease complications of influenza disease during their pregnancies. Recent data also support maternal immunization for the additional purpose of preventing disease in the infant during the first six months of life. |
| |
| Keywords: | AEFI, adverse event following immunization ALRI, acute lower respiratory infections EMA, European Medicines Agency EPI, Expanded Programme on Immunization FDA, United States Food and Drug Administration GACVS, WHO Global Advisory Committee on Vaccine Safety H1N1, 2009 pandemic influenza A (H1N1) MNCH, Maternal, Newborn, and Child Health MNT, Maternal and Neonatal Tetanus NITAG, national immunization technical advisory groups NRA, national regulatory authorities PAHO, Pan American Health Organization PCV, pneumococcal conjugate vaccine PPV, pneumococcal polysaccharide vaccine SAGE, WHO Strategic Advisory Group of Experts on Immunization SGA, small for gestational age SIVAC, Supporting Independent Immunization and Vaccine Advisory Committees Initiative TIV, trivalent inactivated influenza vaccine TT, tetanus-toxoid (TT) - containing vaccines VICP, US National Vaccine Injury Compensation Program |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
